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The effect inflammation has on cancer prognosis is marked by the presence of cytokines and 2 
chemokines. Interleukin-6 (IL-6) is one a multifunctional cytokine that regulates inflammatory 3 
responses. We investigated the roles of IL-6 and STAT3 and examined the relationship between IL-6 4 
signaling and clinicopathological factors in patients with oral squamous cell carcinoma (OSCC). We 5 
retrospectively examined 116 patients who underwent radical surgery for OSCC. IL-6 and STAT3 6 
expression were detected by immunohistochemistry. IL-6 and STAT3 positivity were detected by IHC, 7 
at 78.4 and 80.2%, respectively. IL-6 expression was significantly associated with pattern of invasion 8 
(P = 0.004), vascular invasion (P = 0.003), and pathological nodal status (P = 0.019). Multivariate 9 
logistic regression analysis revealed that IL-6 expression was significantly associated with vascular 10 
invasion (P = 0.044). Meanwhile, there was no significant association between STAT3 expression and 11 
clinicopathological factors and no significant relationship between IL-6 and STAT3 expression. IL-6 12 
expression was significantly associated with 5-year disease-free survival. These results suggest that 13 
IL-6 is involved in lymphangiogenesis and recurrence in OSCC. 14 
 15 
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Oral squamous cell carcinoma (OSCC) accounts for 2−3% of all cancers and is the 11th most common 2 
cancer worldwide [1]. OSCC remains a major cause of morbidity and mortality in patients with head 3 
and neck cancer. Despite excellent functional and survival outcomes in patients with early-stage oral 4 
cancer, patients with advanced-stage disease continue to have poor survival, with only a 5% 5 
improvement in overall survival in the last 20 years [2]. Therefore, more effective treatment strategies 6 
are necessary to improve the survival of patients with OSCC. With advances in tumor immunology, 7 
immunotherapy has become an emerging option for cancer therapy [3,4]. Recently, several studies 8 
have reported that biomarkers involved in inflammation and the immune system are useful for 9 
understanding the biological behavior of OSCC [5–10]. 10 
Previous studies have reported that inflammation affects cancer prognosis [11–19]. IL-6 is a 11 
multifunctional cytokine that regulates inflammatory responses [20]. IL-6 plays an important role in 12 
many tumor functions, including development, migration, invasion, growth, proliferation, apoptosis, 13 
progression, angiogenesis, and differentiation of tumor cells [21]. IL-6 activates the Janus 14 
kinase/signal transducer and activator of transcription (JAK/STAT) pathway, phosphatidylinositol-3 15 
kinase (PI3K) pathway, and the mitogen-activated protein kinase (MAPK) pathway [22]. IL-6 binds to 16 
IL-6R, which forms a complex with gp130, to activate STAT3 via the JAK/STAT pathway [12, 21, 23]. 17 
Activated STAT3 controls proliferation, survival, inflammation, invasion, metastasis, and angiogenesis 18 
in normal cells [21,23,24]. However, activated STAT3 induces pro-survival and pro-proliferative 19 
signaling and contributes to tumor growth of cancer cells [24]. However, few studies have examined 20 
the relationship between IL-6 signaling and OSCC biological characteristics. Therefore, we 21 
investigated the roles of IL-6 and STAT3 in OSCC and examined the relationship between IL-6 22 
signaling and clinicopathological factors of patients with OSCC. 23 
  24 
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Materials and Methods 1 
 2 
Patient characteristics 3 
We analyzed data from 116 patients with OSCC who had their first visit to our department between 4 
April 2008 and March 2013 and were treated, usually with surgery. Ethical approval was obtained 5 
from the institutional review board of Nagasaki University Hospital (IRB no.: 15061128). Patients 6 
who underwent preoperative chemotherapy or radiation therapy or who had insufficient preoperative 7 
records were excluded. All patients underwent extensive pretreatment evaluations, including blood 8 
chemistry analysis, complete blood count, chest X-ray, computed tomography (CT), and/or magnetic 9 
resonance imaging (MRI) of the head and neck area, and thoracoabdominal CT, and staging using the 10 
TNM classification of malignant tumors, UICC 7th edition [25]. 11 
The pattern of invasion (POI), which was evaluated as types 1–4 as defined previously by Bryne et 12 
al. [26], was examined at the host/tumor interface. Perineural invasion was defined as the presence of 13 
tumor cells within any of the three layers of the nerve sheath (the epineurium, perineurium, and 14 
endoneurium). Vascular invasion was defined as the clear presence of tumor cells within a vascular 15 
space (lymphatic space or blood vessel), and the tumor had to be adhered to the vessel endothelium or 16 
attached to a thrombus in the vessel. 17 
 18 
Immunohistochemistry (IHC) 19 
Biopsy or surgical specimens were taken from the patient with OSCC, formalin-fixed, and 20 
paraffin-embedded after surgery. Specimens were cut into 4-μm serial sections. Serial sections were 21 
deparaffinized in xylene, soaked in 10 mM citrate buffer (pH 6), and placed in the autoclave at 121°C 22 
for 5 min for antigenicity activation. Endogenous peroxidase was blocked with 0.3% H2O2 in 23 
methanol at room temperature for 30 min. The sections were incubated with primary antibodies (IL6, 24 
Abcam, Cambridge, UK; 1:600 dilution and STAT3, 124H6, Cell Signaling Technology, MA, USA; 25 
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1:600 dilution) overnight at 4°C. Immunohistochemical staining was performed with the EnVision 1 
system (EnVision+, DAKO, Glostrup, Denmark). Reaction products were visualized using 2 
diaminobenzidine (DAB) solution, counterstained with Mayer’s hematoxylin, dehydrated, cleared with 3 
xylene, and mounted. Immunohistochemistry expression analyses were performed by calculating the 4 
sum of distribution scores and intensity scores. The distribution score was defined as the estimated 5 
fraction of positively stained tumor area (0: none, 1: <20%, 2: 20–50%, 3: 50–80%, and 4: >80%). The 6 
intensity score was defined as the estimated staining intensity (0: no staining, 1: weak, 2: moderate, 7 
and 3: strong). Total scores ranged from 0 to 7. Score of 5 or more were determined positive 8 
expression by Receiver Operating Characteristic (ROC) analysis. 9 
 10 
Measurement of C-reactive protein (CRP) level and neutrophil-to-lymphocyte ratio (NLR)  11 
All serum CRP levels and complete blood counts were measured during preoperative examination. 12 
NLR values were calculated using neutrophil and lymphocyte counts. The optimal cut-off value for 13 
CRP was 3 mg/L, and the NLR cutoff was 2.4, as previously reported [7,14]. 14 
 15 
Statistical Analysis 16 
All analyses were performed using SPSS 22.0 (Japan IBM, Tokyo, Japan). Categorical data were 17 
assessed by Chi-squared test. Multivariate logistic regression analyses were used to determine the 18 
associations between various factors and IL-6 expression. Survival times were calculated from the date 19 
of surgery. Disease-free survival (DFS) was defined as the period from the date of surgery to cancer 20 
recurrence. Disease-specific survival (DSS) was defined as the period from the date of surgery to 21 
death or the end of observation. DFS and DSS of the entire cohort were estimated using the 22 
Kaplan-Meier method and compared by log-rank test. Multivariate analyses were assessed using the 23 
Cox proportional hazards model. Significant factors from univariate analyses were included in 24 





Patient characteristics 3 
Patient demographic characteristics are summarized in Table 1. The mean age at diagnosis was 67.4 4 
years (range, 30–95 years). The male-to-female ratio was 1.27, with 65 male subjects. Diffuse invasion 5 
was found in 42 of 116 patients (36.2%), vascular invasion was found in 54 patients (46.6%), and 6 
perineural invasion was found in 27 patients (23.3%). Pathological lymph node metastasis was noted 7 
in 42 patients (36.2%). Local recurrence developed in 11 patients (9.5%) during the follow-up period, 8 
which was a mean 48.9 months for all participants (range, 2–88 months). 9 
 10 
IL-6 and STAT3 expression by IHC 11 
IL-6 was strongly expressed in stroma and cancer cell membranes, but it was not expressed in cancer 12 
cell cytoplasm (Fig. 1a). STAT3 was strongly expressed in cancer cell membranes and nuclei (Fig. 1b). 13 
IL-6 and STAT3 positivity rates by IHC were 78.4 and 80.2%, respectively. 14 
 15 
Associations between IL-6 and STAT3 expression, clinicopathological factors, and survival 16 
IL-6 and STAT3 expression levels are summarized in Table 1. IL-6 expression was significantly 17 
associated with POI, vascular invasion, and pathological nodal status. Multivariate logistic regression 18 
analysis revealed that IL-6 expression was significantly associated with vascular invasion (P = 0.044) 19 
(Table 2). Meanwhile, there was no significant association between STAT3 expression and 20 
clinicopathological factors. There was no significant relationship between IL-6 and STAT3 expression 21 
(Table 3). Univariate analyses by log-rank test revealed that POI (P < 0.001), vascular invasion (P < 22 
0.001), perineural invasion (P < 0.001), pathological nodal status (P < 0.001), and IL-6 (Fig. 2, P = 23 
0.010) were significantly associated with 5-year DFS. Predictors associated with 5-year DFS in 24 
univariate analyses were included in the Cox proportional hazards model, and this multivariate 25 
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analysis showed that POI and pathological nodal status were independent predictors of 5-year DFS. 1 
Univariate analyses by log-rank test revealed that clinical stage (P = 0.032), POI (P < 0.001), vascular 2 
invasion (P = 0.026), perineural invasion (P = 0.004), and pathological nodal status (P < 0.001) were 3 
significantly associated with 5-year DSS. According to the Cox proportional hazards multivariate 4 




IL-6 is a multifunctional cytokine that regulates immune responses [20]. IL-6 production is increased 9 
in response to various stimuli, such as infection and inflammation. Cancer stimulates inflammation 10 
that can lead to increased expression of IL-6-modulating factors, such as IL-1β, COX-2, PGE2, and 11 
TGF-β [22]. The IL-6 receptor is a type I cytokine receptor complex that consists of the ligand-binding 12 
IL-6Ra chain (also called CD126) and the gp130 (also called CD130), which is responsible for 13 
downstream signaling [21]. IL-6 activates the JAK/STAT, PI3K, and the MAPK pathways [8,22]. This 14 
signaling influences cell migration, malignant tumor growth and invasion, anti-apoptotic signaling, 15 
angiogenesis, and bone remodeling [8–10,22,27,28]. 16 
Shinriki et al. demonstrated that IL-6 signaling via the PI3K-Akt pathway stimulates VEGF-C 17 
synthesis and lymphangiogenesis in OSCC [27]. VEGF-C is an essential chemotactic and survival 18 
factor during embryonic and inflammatory lymphangiogenesis [29]. Furthermore, several studies have 19 
reported that the VEGF-C is associated with lymph node metastasis, and its expression is a prognostic 20 
factor for various cancers including oral cancer [30–32]. In this study, we examined the association 21 
between IL-6 expression and clinicopathological factors in patients with OSCC by IHC. Our data 22 
indicate that IL-6 expression is associated with POI, vascular invasion, and pathological nodal status 23 
in OSCC. In particular, vascular invasion strongly correlated with IL-6 expression, suggesting that 24 
IL-6 is involved in lymphangiogenesis in OSCC.  25 
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On the other hand, several studies have reported that IL-6 activates the JAK/STAT3 pathway in 1 
various cancers [12,15,24,28]. Yadav et al. demonstrated that IL-6 promotes epithelial-mesenchymal 2 
transition (EMT) changes via the JAK/STAT3 pathway [28]. STAT3 is downstream mediator of IL-6 3 
and represses E-cadherin transcription via the snail-related zinc-finger transcription factor [28]. 4 
E-cadherin loss in tumor cells is a widely known hallmark of EMT. Additionally, some studies have 5 
reported that IL-6 overexpression plays transcriptional and regulatory roles in invasion and metastasis, 6 
leading to poor prognoses for patients with head and neck cancers [9,17,22,24,28]. In this study, 7 
however, the relationship between IL-6 and STAT3 expression was not significant. In addition, STAT3 8 
was not significantly associated with clinicopathological factors. Therefore, our results suggested that 9 
IL-6 promotes lymphangiogenesis via the PI3K-Akt pathway rather than the JAK/STAT3 pathway. 10 
Some studies reported that post-operative serum or salivary IL-6 levels could predict recurrence 11 
and survival in patients with head and neck cancer [9,10,33]. Sato et al. indicated that post-operative 12 
salivary IL-6 level is a useful marker for OSCC locoregional recurrence [10]. In this study, IL-6 13 
expression was significantly associated with 5-year DFS, suggesting that IL-6 evaluation by IHC 14 
could predict time to recurrence, including locoregional recurrence and distant metastasis. However, 15 
any correlation between IL-6 expression and local recurrence was not clear, leading us to conclude that 16 
IL-6 was primarily involved in lymphangiogenesis and metastasis of OSCC. 17 
CRP and NLR are indicators of inflammatory response and often checked at during preoperative 18 
examination. Tumor growth can cause tissue inflammation and an immune response to tumor antigens 19 
[11,12]. Furthermore, IL-6 secreted by cancer cells induces CRP production, which is a tumor antigen 20 
that links chronic inflammation and tumor growth [14¬–17]. Leukocyte count is usually increased in 21 
response to infection, inflammation, allergic reaction, and malignancy. Although neutrophils have 22 
anti-tumor effects, lymphocytes are most responsible for controlling cancer progression, and 23 
increasing NLR is less efficacious [18]. Therefore, NLR elevation has been suggested to be associated 24 
with poor prognosis. Some studies report a relationship between prognosis and both high preoperative 25 
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CRP levels and NLR [5,7,19]. Tumor cells produce various cytokines and chemokines that induce 1 
inflammatory responses, including a diverse leukocyte population, cytokines, and cytotoxic mediators 2 
[11]. This study found no relationship between IL-6 or STAT3 expression and increasing preoperative 3 
CRP levels or NLR in OSCC. In our study, the proportion of patients with high CRP levels was small 4 
compared with that of other reports [5,7]. In cases of oral cancer, when the differential diagnosis 5 
includes acute dental infection, antibiotics are administered early. Inflammation-related oral cancer 6 
becomes suspected when chronic inflammation remains, with no CRP level elevation. Some studies 7 
reported that elevated NLR is associated with worse prognosis [7,19]. Neutrophils induced by GCSF 8 
from the tumor aid in tumor progression by producing chemical mediators, such as VEGF, and causing 9 
a relative reduction in lymphocyte number and a decrease in lymphocyte-dependent cellular immune 10 
reactions [18,34,35]. Because lymphocyte-mediated cellular immune responses are reduced when 11 
NLR is high, high NLR is often seen in tumor progression and is a predictor of poor prognosis [18]. In 12 
this study, the relationship between IL-6 and STAT3 expression and increased preoperative NLR was 13 
not significant. Recent studies have reported that elevated NLR could be used to predict response to 14 
neoadjuvant chemoradiation and prognosis in rectal cancer [36,37]. Therefore, if patients with lower 15 
baseline NLR values underwent neoadjuvant chemoradiation, they would be more likely to have better 16 
responses. We could not evaluate the relationship between NLR value and neoadjuvant therapy 17 
efficacy because patients who underwent neoadjuvant chemoradiation or chemotherapy were not 18 
included in our cohort. 19 
In conclusion, our data indicate that IL-6 expression is associated with POI, vascular invasion, and 20 
pathological nodal status in OSCC. In particular, vascular invasion strongly correlated with IL-6 21 
expression but not STAT3. Therefore, the present study suggests that IL-6 involved in 22 
lymphangiogenesis and recurrence in OSCC. Further studies to elucidate the mechanism of 23 
IL-6-mediated VEGF-C synthesis may provide information leading to the development of treatment 24 
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Figure Legends 1 
Fig. 1 Representative immunohistochemical staining for IL-6 and STAT3 in OSCC. a: IL-6 was 2 
strongly positive in cell stroma and on cancer cell membranes(intensity score 3), but there was no IL-6 3 
staining in the cancer cell cytoplasm. b: STAT3 was strongly expressed in cancer cell membranes and 4 
nuclei (intensity score 3). 5 
 6 
Fig. 2 Kaplan-Meier curves for 5-year disease-free survival according to IL-6 expression in patients 7 
with OSCC. The IL-6 overexpression group had a significantly lower disease-free survival rate than 8 








Table 1 Association of IL-6 and STAT3 with clinicopathological factors 
Characteristics 
No. of cases 
(%) 
IL-6 STAT3 
Negative Positive P Negative Positive P 
Age (years) 
  <65 
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Bolded values indicate p <0.05. 
POI, Pattern of invasion; CRP, C-reactive protein; NLR, Neutrophil-to-lymphocyte ratio. 
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Bolded values indicate p <0.05. 
POI, Pattern of invasion; HR, hazard ratio; CI, confidence interval. 
Table 3 Relationship between IL-6 expression and STAT3 expression 
 
STAT3 expression 
Negative (n=23) Positive (n=93)  
IL-6 expression 










Table 4 Univariate and multivariate analyses of risk factors influencing survival 
Characteristics 
Disease free survival Disease specific survival 
Univariate Multivariate Univariate Multivariate 
5-year 
DFS 
pa HR (95% CI) p 5-year 
DSS 
p HR (95% CI) p 
Age (years) 
  <65 























  Male 











Clinical T stage 
  T1−2 




0.065 - -  
83.5% 
76.6% 
0.588 - - 
Clinical stage 
  Stage I-II 



















































  No 




















  No 



















  <3 












  <2.4 




0.482 - -  
78.1% 
86.6% 
0.351 - - 
IL-6 
  Negative 










0.126 - - 
STAT3 
  Negative 




0.338 - -  
93.8% 
78.7% 
0.184 - - 
aBolded values indicate p <0.05. 
POI, Pattern of invasion; CRP, C-reactive protein; NLR, Neutrophil-to-lymphocyte ratio. 
